Associations - PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA rearrangement	Myelodysplastic Syndrome	PDGFRA rearrangement	Myelodysplastic Syndrome	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
PDGFRA D842V	Gastric Cancer	PDGFRA D842V	Gastric Cancer	imatinib Resistant: A2 - Guideline imatinib Resistant : A2	imatinib Resistant: A2 - Guideline imatinib Resistant : A2
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: A2 - Guideline ripretinib Sensitive : A2	ripretinib Sensitive: A2 - Guideline ripretinib Sensitive : A2
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
PDGFRA mutation	Gastric Cancer	PDGFRA mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
PDGFRA T301T	Colorectal Cancer	PDGFRA T301T	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
PDGFRA mutation	Non Small Cell Lung Cancer	PDGFRA mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PDGFRA R841K	Melanoma	PDGFRA R841K	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA V658A	Melanoma	PDGFRA V658A	Melanoma	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
PDGFRA V658A	Melanoma	PDGFRA V658A	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA R841K	Melanoma	PDGFRA R841K	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRA P577S	Melanoma	PDGFRA P577S	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRA P577S	Melanoma	PDGFRA P577S	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA H845Y	Melanoma	PDGFRA H845Y	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRA H845Y	Melanoma	PDGFRA H845Y	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA G853D	Melanoma	PDGFRA G853D	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRA G853D	Melanoma	PDGFRA G853D	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA I843_D846delIMHD	Gastrointestinal Stromal Tumor	PDGFRA I843_D846delIMHD	Gastrointestinal Stromal Tumor	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
PDGFRA expression	Renal Cell Carcinoma	PDGFRA expression	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
PDGFRA mutation	Non Small Cell Lung Cancer	PDGFRA mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PDGFRA rs2228230	Squamous Cell Carcinoma of Head and Neck	PDGFRA rs2228230	Squamous Cell Carcinoma of Head and Neck	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
PDGFRA rs2228230	Squamous Cell Carcinoma of Head and Neck	PDGFRA rs2228230	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3

PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

Associations(56)

Associations
(56)